Acute Lymphoblastic Leukemia News and Research

RSS

Acute lymphoblastic leukemia (ALL) is a cancer of the white blood cells, the cells in the body that normally fight infections. There are two main types of white blood cells-lymphoid cells and myeloid cells. ALL affects lymphoid cells.

Oxford Finance Corporation announces $25M credit facility to EUSA Pharma

Oxford Finance Corporation today announced that it is the agent and primary lender for a $25 million credit facility provided to EUSA Pharma. MidCap Financial and Silicon Valley Bank are co-lenders in the transaction.

5 Feb 2010

ERYtech Pharma receives ODD for its GRASPA from FDA

ERYtech Pharma announces that FDA has granted an Orphan Drug Designation (ODD) for GRASPA®, the company’s lead product in Acute Lymphoblastic Leukaemia.

27 Jan 2010

Postdoctoral scientists receive prestigious award; grants totaling $1.54 million will help in funding innovative projects

The Damon Runyon Cancer Research Foundation, a non-profit organization focused on supporting exceptional early career researchers and innovative cancer research, named 11 new Damon Runyon Fellows at its November 2009 Fellowship Award Committee review.

22 Jan 2010

Australian scientists discover cells that cause a common type of childhood leukaemia

Scientists at The Royal Melbourne Hospital and the University of Melbourne in Australia have discovered the cells that cause a common type of childhood leukaemia - T cell Acute Lymphoblastic Leukaemia (T-ALL). Targeting of these cells may lead to improved treatments for this disease and help prevent relapse.

22 Jan 2010

New research may yield more effective treatment for childhood leukemia

A team of Israeli scientists at the Sheba Medical Center's Research Center for Leukemia and Childhood Malignancies has discovered a method for developing a more effective and less perilous treatment for those suffering from childhood leukemia, the most common cancer in children.

6 Jan 2010

John Theurer Cancer Center presents over 20 research updates and trial results at the 2009 ASH meeting

Doctors and researchers from the John Theurer Cancer Center at Hackensack University Medical Center recently presented research updates and clinical trial results of more than 20 innovative studies at the American Society of Hematology (ASH) annual meeting from December 5-8, 2009.

18 Dec 2009

Herb milk thistle help treat liver inflammation in cancer patients who receive chemotherapy, finds study

A new study finds that the herb milk thistle may help treat liver inflammation in cancer patients who receive chemotherapy. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the study indicates that the herb could allow patients to take potent doses of chemotherapy without damaging their liver.

14 Dec 2009

Tasigna demonstrates greater efficacy over Gleevec in chronic Ph+ CML patients

In a large Phase III clinical trial, Tasigna (nilotinib capsules) demonstrated greater efficacy over Gleevec (imatinib) in the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. The new clinical data were just presented as a late breaking abstract at the 51st annual meeting of the American Society of Hematology (ASH), in New Orleans, Louisiana.

11 Dec 2009

Micromet presents final data from its blinatumomab Phase 2 study for ALL

Micromet, Inc., a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced data from its completed phase 2 clinical trial with blinatumomab in patients with B-precursor acute lymphoblastic leukemia (ALL).

8 Dec 2009

Positive data from ARIAD Pharmaceuticals' ongoing AP24534 study in advanced hematological cancer patients

ARIAD Pharmaceuticals, Inc. today announced positive clinical data from an ongoing Phase 1 study of its investigational, pan-BCR-ABL inhibitor, AP24534, in patients with advanced hematological cancers.

8 Dec 2009

New findings may yield more effective therapies for infants with blood cancer

Pediatric oncologists have identified specific genes, dubbed partner genes, that fuse with another gene to drive an often-fatal form of leukemia in infants. By more accurately defining specific partner genes, researchers expect to better predict which infants may benefit from particular treatments.

7 Dec 2009

New treatment options for leukemia and myeloproliferative disorders introduced

Leukemia and myeloproliferative disorders are serious and often deadly blood cancers. Research presented today at the 51st Annual Meeting of the American Society of Hematology introduces potential new treatment options and improved diagnostic methods for patients suffering from acute promyelocytic leukemia, chronic myeloid leukemia, infant acute lymphoblastic leukemia, and myelofibrosis that are based on a better understanding of the underlying genetic causes of these conditions.

6 Dec 2009

More than 80 abstracts highlighting Bristol-Myers Squibb's oncology compound to be presented

Bristol-Myers Squibb Company today announced that more than 80 abstracts highlighting compounds from the company’s oncology portfolio will be presented at the 51st Annual Meeting of the American Society of Hematology (ASH) to be held December 5-8 in New Orleans.

3 Dec 2009

Micromet to present new results from its blinatumomab study at the ASH meeting

Micromet, Inc., a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that it will present new results from its clinical studies with blinatumomab at the 51st annual meeting of the American Society of Hematology from December 5-8, 2009 in New Orleans, Louisiana.

30 Nov 2009

Phase 1 data of ARIAD Pharmaceuticals' pan-BCR-ABL inhibitor to be presented at the ASH meeting

ARIAD Pharmaceuticals, Inc. today announced that the Company and collaborating investigators from five major oncology research centers in the United States will present data from a Phase 1 clinical trial of ARIAD’s investigational, multi-targeted kinase inhibitor and pan-BCR-ABL inhibitor, AP24534, at the 51st Annual Meeting of the American Society of Hematology (ASH) being held in New Orleans, Louisiana, December 5-8, 2009.

23 Nov 2009

Data on Synta Pharmaceuticals' STA-9090 synthetic inhibitor of Hsp90 presented

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that preclinical data presented at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics shows that STA-9090, a novel, synthetic inhibitor of heat shock protein 90 (Hsp90), demonstrated strong activity in multiple tumor models.

18 Nov 2009

Asuragen enters into an exclusive agreement with Life Technologies

Asuragen, Inc. announced today that it has entered into an exclusive agreement with Life Technologies Corporation to develop and distribute worldwide an in-vitro diagnostic test intended to aid clinicians in the monitoring and treatment of individuals afflicted with chronic myeloid leukemia (CML).

18 Nov 2009

Two units of UCB reduce risk of leukemia from returning, shows new study

A new study from the Masonic Cancer Center, University of Minnesota shows that patients who have acute leukemia and are transplanted with two units of umbilical cord blood (UCB) have significantly reduced risk of the disease returning.

16 Nov 2009

Stapled Peptides directly inhibit the Notch transcription factor complex

Aileron Therapeutics, a biopharmaceutical company leading the development of a new class of drugs called Stapled Peptides, announced today that its collaborators, James E. Bradner, MD of the Dana-Farber Cancer Institute and the Broad Institute of Harvard and MIT, and Gregory L. Verdine, PhD, Professor of Chemistry at Harvard University, published research in Nature entitled, “Direct Inhibition of the Notch Transcription Factor Complex.”

12 Nov 2009

Stapled Peptides can inhibit key intracellular biological targets, says new research

Aileron Therapeutics, a biopharmaceutical company leading the development of a new class of drugs called Stapled Peptides, announced today that its collaborators, James E. Bradner, MD of the Dana-Farber Cancer Institute and the Broad Institute of Harvard and MIT, and Gregory L. Verdine, PhD, Professor of Chemistry at Harvard University, published research in Nature entitled, "Direct Inhibition of the Notch Transcription Factor Complex." Results presented in the paper showed that Stapled Peptides can potently and directly inhibit the transcription factor Notch, an oncogene implicated in cancer cell proliferation and survival.